Blog

Evaluating molecularly guided therapies beyond tumor type – ESMO

Photo of Benedikt Westphalen taken from LinkedIn

Feb 20, 2025, 10:45

Evaluating molecularly guided therapies beyond tumor type – ESMO

ESMO shared a post on X:

“The ESMO Tumor-Agnostic Classifier and Screener (ETAC-S) introduces a framework for evaluating molecularly guided therapies beyond tumor type.

Where does Liquid Biopsy fit in?

Enables non-invasive genomic profiling for tumor-agnostic therapies

Detects targetable alterations in ctDNA for real-time treatment decisions

Supports longitudinal monitoring of treatment response and resistance.

Liquid biopsy is shaping the future of molecular screening and tumor-agnostic precision oncology!

Learn more.”

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Authors: C.B. Westphalen et al.

molecularly guided therapies

A. Marabelle A.M. Schram C. Cardone C. Marchió C. Yap C.B. Westphalen cancer D. Martins Branco E. Garralda F. André F. Bibeau G Curigliano G Pentheroudakis J. Mateo J. Rodon J.R. Beal N. Coleman OncoDaily Oncology R. Kurzrock S. Halabi S. Kummar S. Limaye S. Loges S. Michiels T. Spanic V Subbiah

Does Artificial Sweeteners Cause Cancer? Myths and Facts

King Charles III Hospitalized Following Side Effects from Cancer Treatment

Keith T. Flaherty has been elected as the AACR President-Elect for 2025-2026

MARIPOSA trial results presented at ELCC25 - BREAKING from Paris

Miranda McKeon: Battling Breast Cancer at 19, Inspiring Millions on Instagram